--- title: "Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg" type: "News" locale: "en" url: "https://longbridge.com/en/news/289012868.md" description: "Roche and Nurix Therapeutics signed a $2.3 billion collaboration to co-develop and commercialize bexobrutideg, an investigational BTK degrader. The deal includes a $700 million upfront payment, with potential milestones reaching the total value. Development costs are split 60/40 between Roche and Nurix, respectively. Profits in the U.S. are shared equally, while Roche leads international commercialization with royalties for Nurix. The transaction is expected to close in Q3 2026." datetime: "2026-06-08T06:52:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289012868.md) - [en](https://longbridge.com/en/news/289012868.md) - [zh-HK](https://longbridge.com/zh-HK/news/289012868.md) --- # Roche And Nurix Ink $2.3 Bln Collaboration To Co-Develop BTK Degrader Bexobrutideg Add as your preferred news source on Google Add Now Roche (RHHBY) announced it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NRIX). The two companies will co-develop and co-commercialise bexobrutideg (NX-5948), Nurix's investigational Bruton's Tyrosine Kinase (BTK) degrader. The collaboration spans a clinical development plan across B-cell malignancies, immunology, and neurology, complementing Roche's established strengths in haematology while extending its pipeline into new therapeutic areas. As per the terms of the agreement, Nurix will receive an upfront cash payment of US$700 million and is eligible for development, regulatory, and sales milestones, bringing the potential total deal value to US$2.3 billion. Development costs will be shared, with Nurix covering 40% and Roche 60%. Profits and losses from U.S. commercialisation will be split equally, while outside the U.S., Roche will lead commercialisation and Nurix will receive royalties ranging from the low- to high-teens. The transaction is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The parties currently expect the transaction to close in the third quarter of 2026. Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially diseases in immunology and neurology. BTK is a central signaling node controlling B cell growth, development and immunologic activity. NRIX closed at $14.64 on June 5, down $0.64 or 4.19%. However, in overnight trading, the stock surged to $17.48, up $2.84 or 19.40%. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md) ## Related News & Research - [](https://longbridge.com/en/news/289066296.md) - [Roche Develops Ebola PCR Test In Six Days Amid Bundibugyo Outbreak](https://longbridge.com/en/news/288802796.md) - [Roche’s Giredestrant Review Puts Early Breast Cancer Franchise In Focus](https://longbridge.com/en/news/288892413.md) - [Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics](https://longbridge.com/en/news/289087845.md) - [](https://longbridge.com/en/news/288460866.md)